National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

MET tyrosine kinase inhibitor PF-02341066
An orally bioavailable agent belonging to the class of c-met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors with potential antineoplastic activity. MET tyrosine kinase inhibitor PF-02341066 inhibits the membrane receptor MET and activation of the MET signaling pathway, which may block tumor cell growth, migration and invasion, and tumor angiogenesis in susceptible tumor cell populations. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:c-met/hepatocyte growth factor receptor tyrosine kinase inhibitor PF-02341066
c-met/HGFR tyrosine kinase inhibitor PF-02341066
Code name:PF-02341066



Previous:mesna, Mesnex, mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine, MET receptor tyrosine kinase inhibitor SGX523, Met tyrosine kinase inhibitor BMS-777607
Next:MET tyrosine kinase inhibitor PF-04217903, Metastat, Metastron, metformin hydrochloride, methadone hydrochloride

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov